Razzetti R, Bongrani S, Oberto G, Ferrari R, Biagini G
Department of Pharmaco-toxicology, Chiesi Farmaceutici S.p.A., Parma, Italy.
Arzneimittelforschung. 1998 Nov;48(11):1083-7.
The effects of long-term oral administration of delapril (CAS 83435-67-0), indapamide (CAS 26807-65-8) and their combination on the occurrence of stroke and on mortality were investigated in young salt-loaded stroke-prone spontaneously hypertensive rats (SHRsp) for 31 weeks of treatment (8th-39th week of age) and up to 8 weeks thereafter. Body weight and saline consumption were investigated at regular intervals and cerebrovascular lesions, renal and heart weight were assessed after sacrifice. Untreated SHRsp served as controls. About 50% of control animals died within 6 weeks of saline administration and in 56% of surviving animals cerebral lesions were present at sacrifice, while no death and no cerebral lesions were observed in animals drinking saline, to which delapril, indapamide and their combination had been added, up to the end of treatment. This protective effect was maintained even in the withdrawal period. All treatments induced a highly significant (p < 0.001) reduction of heart weight/body weight and kidney weight/body weight ratios.
在年轻的盐负荷易中风自发性高血压大鼠(SHRsp)中,研究了长期口服地拉普利(CAS 83435-67-0)、吲达帕胺(CAS 26807-65-8)及其组合对中风发生率和死亡率的影响,治疗期为31周(8至39周龄),此后长达8周。定期测量体重和盐水消耗量,并在处死动物后评估脑血管病变、肾脏和心脏重量。未治疗的SHRsp作为对照。约50%的对照动物在给予盐水后6周内死亡,56%存活的动物在处死时有脑损伤,而在添加了地拉普利、吲达帕胺及其组合的饮用盐水中的动物,直至治疗结束均未观察到死亡和脑损伤。即使在撤药期,这种保护作用仍得以维持。所有治疗均使心脏重量/体重和肾脏重量/体重比值显著降低(p < 0.001)。